The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
Abstract
ADVERTISEMENT RETURN TO ISSUEReviewNEXTContemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer ChemotherapyChristian Bailly*View Author Information Centre de Recherche et Développement, Institut de Recherche Pierre Fabre, 3 Avenue Hubert Curien, BP 13562, 31035 Toulouse cedex 1, France*E-mail: [email protected]Cite this: Chem. Rev. 2012, 112, 7, 3611–3640Publication Date (Web):March 8, 2012Publication History Received20 August 2011Published online8 March 2012Published inissue 11 July 2012https://pubs.acs.org/doi/10.1021/cr200325fhttps://doi.org/10.1021/cr200325freview-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views6871Altmetric-Citations238LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Cells,Genetics,Inhibitors,Peptides and proteins,Toxicity Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Prasad, S., Pandey, M. K., Yadav, V. R., & Aggarwal, B. B. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0340 · Cited by 52
RetractedDNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
DNA topoisomerase II and its growing repertoire of biological functions
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2608 · Cited by 885
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., et al. (2010) · Nature · doi:10.1038/nature09197 · Cited by 860
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
Quinolone-Mediated Bacterial Death
Drlica, K., Malik, M., Kerns, R. J., & Zhao, X. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01617-06 · Cited by 570
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., Yen, T.-J., Chiang, C.-W., & Chan, N.-L. (2011) · Science · doi:10.1126/science.1204117 · Cited by 523
Bancaud, A., Huet, S., Daigle, N., Mozziconacci, J., Beaudouin, J., & Ellenberg, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.340 · Cited by 447
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Structure, Molecular Mechanisms, and Evolutionary Relationships in DNA Topoisomerases
Corbett, K. D., & Berger, J. M. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140357 · Cited by 426
A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage
Ledesma, F. C., El Khamisy, S. F., Zuma, M. C., Osborn, K., & Caldecott, K. W. (2009) · Nature · doi:10.1038/nature08444 · Cited by 408
DNA topoisomerase II, genotoxicity, and cancer
McClendon, A. K., & Osheroff, N. (2007) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2007.06.009 · Cited by 406
Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
Strick, R., Strissel, P. L., Borgers, S., Smith, S. L., & Rowley, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070061297 · Cited by 390
The role of chalcones in suppression of NF-κB-mediated inflammation and cancer
Yadav, V. R., Prasad, S., Sung, B., & Aggarwal, B. B. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.12.006 · Cited by 339
Lovejoy, D. B., Jansson, P. J., Brunk, U. T., Wong, J., Ponka, P., & Richardson, D. R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1218 · Cited by 308
Baviskar, A. T., Madaan, C., Preet, R., Mohapatra, P., Jain, V., Agarwal, A., Guchhait, S. K., Kundu, C. N., Banerjee, U. C., & Bharatam, P. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200235u · Cited by 294
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Azarova, A. M., Lyu, Y. L., Lin, C.-P., Tsai, Y.-C., Lau, J. Y.-N., Wang, J. C., & Liu, L. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704002104 · Cited by 286
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1177-4 · Cited by 229
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 222
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
Morgan, G., Ward, R., & Barton, M. (2004) · Clinical Oncology · doi:10.1016/j.clon.2004.06.007 · Cited by 221
Xu, H., Lv, M., & Tian, X. (2008) · Current Medicinal Chemistry · doi:10.2174/092986709787002682 · Cited by 200
Podophyllotoxin Derivatives: Current Synthetic Approaches for New Anticancer Agents
You, Y. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764724 · Cited by 199
Huang, H., Chen, Q., Ku, X., Meng, L., Lin, L., Wang, X., Zhu, C., Wang, Y., Chen, Z., Li, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9014394 · Cited by 197
A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases
Schmidt, B. H., Burgin, A. B., Deweese, J. E., Osheroff, N., & Berger, J. M. (2010) · Nature · doi:10.1038/nature08974 · Cited by 186
Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases
Laponogov, I., Pan, X.-S., Veselkov, D. A., McAuley, K. E., Fisher, L. M., & Sanderson, M. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011338 · Cited by 178
Keating, G. M. (2010) · Drugs · doi:10.2165/11201110-000000000-00000 · Cited by 175
Chen, Z., Liang, X., Zhang, H., Xie, H., Liu, J., Xu, Y., Zhu, W., Wang, Y., Wang, X., Tan, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100025u · Cited by 171
Bioflavonoids as Poisons of Human Topoisomerase IIα and IIβ
Bandele, O. J., & Osheroff, N. (2007) · Biochemistry · doi:10.1021/bi7000664 · Cited by 167
Zeng, Z., Cortés-Ledesma, F., El Khamisy, S. F., & Caldecott, K. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.181016 · Cited by 159
Rao, V. A., Klein, S. R., Agama, K., Toyoda, E., Adachi, N., Pommier, Y. G., & Shacter, E. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1437 · Cited by 156
Stimulation of Topoisomerase II-Mediated DNA Damage via a Mechanism Involving Protein Thiolation
Wang, H., Mao, Y., Chen, A. Y., Zhou, N., LaVoie, E. J., & Liu, L. F. (2001) · Biochemistry · doi:10.1021/bi002786j · Cited by 152
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
Salerno, S., Settimo, F. D., Taliani, S., Simorini, F., Motta, C. L., Fornaciari, G., & Marini, A. M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793361252 · Cited by 152
Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
Hawtin, R. E., Stockett, D. E., Byl, J. A. W., McDowell, R. S., Tan, N., Arkin, M. R., Conroy, A., Yang, W., Osheroff, N., & Fox, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010186 · Cited by 148
Preet, R., Mohapatra, P., Mohanty, S., Sahu, S. K., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2011) · International Journal of Cancer · doi:10.1002/ijc.26158 · Cited by 146
Topoisomerase II and the etiology of chromosomal translocations
Felix, C. A., Kolaris, C. P., & Osheroff, N. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.031 · Cited by 145
Camptothecin and Podophyllotoxin Derivatives
Hartmann, J. T., & Lipp, H. (2006) · Drug Safety · doi:10.2165/00002018-200629030-00005 · Cited by 144
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
Al‐Ejeh, F., Kumar, R., Wiegmans, A. P., Lakhani, S. R., Brown, M. P., & Khanna, K. K. (2010) · Oncogene · doi:10.1038/onc.2010.407 · Cited by 142
Gambogic Acid, a Natural Product Inhibitor of Hsp90
Davenport, J., Manjarrez, J. R., Peterson, L. B., Krumm, B., Blagg, B. S. J., & Matts, R. L. (2011) · Journal of Natural Products · doi:10.1021/np200029q · Cited by 131
Lo, Y., Ko, T., Su, W., Su, T., & Wang, A. H. ‐. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.05.006 · Cited by 130
Ché, C., Yang, G., Thiot, C., Lacoste, M.-C., Currie, J.-C., Demeule, M., Régina, A., Béliveau, R., & Castaigne, J.-P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016637 · Cited by 123
Bandele, O. J., Clawson, S. J., & Osheroff, N. (2008) · Chemical Research in Toxicology · doi:10.1021/tx8000785 · Cited by 123
Kikuchi, T., Nihei, M., Nagai, H., Fukushi, H., Tabata, K., Suzuki, T., & Akihisa, T. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.568 · Cited by 111
The polyamine transport system as a target for anticancer drug development
Palmer, A. J., & WALLACE, H. M. (2009) · Amino Acids · doi:10.1007/s00726-009-0400-2 · Cited by 109
Li, X., Lin, Y., Wang, Q., Yuan, Y., Zhang, H., & Qian, X. H. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.050 · Cited by 109
Yu, Y., Rahmanto, Y. S., & Richardson, D. R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01526.x · Cited by 108
Jiang, J., Liang, X., Zhou, X., Huang, L., Huang, R., Chu, Z., & Zhan, Q. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d95c87 · Cited by 108
Synthesis and Antitumor Activity of Quinonoid Derivatives of Cannabinoids
Kogan, N. M., Rabinowitz, R., Levy, P., Gibson, D., Sandor, P., Schlesinger, M., & Mechoulam, R. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040042o · Cited by 107
Toxicity of the topoisomerase II inhibitors
Seiter, K. P. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.2.219 · Cited by 107
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors
Kaushik‐Basu, N., Waffo, A. B., Talele, T. T., Basu, A., Costa, P. R. R., da Silva, A. J. M., Sarafianos, S. G., & Noël, F. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1178 · Cited by 105
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform
Toyoda, E., Kagaya, S., Cowell, I. G., Kurosawa, A., Kamoshita, K., Nishikawa, K., Iiizumi, S., Koyama, H., Austin, C. A., & Adachi, N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803936200 · Cited by 102
Qin, Y., Meng, L., Hu, C., Duan, W., Zuo, Z., Lin, L., Zhang, X., & Ding, J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0147 · Cited by 101
Novel cytotoxic drugs: Old challenges, new solutions
Ismael, G., Rosa, D. D., Mano, M. S., & Awada, A. H. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.08.001 · Cited by 98
Krishnan, P., & Bastow, K. F. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00437-8 · Cited by 95
Robinson, M. J., Corbett, A. H., & Osheroff, N. (1993) · Biochemistry · doi:10.1021/bi00065a016 · Cited by 94
The prince and the pauper. A tale of anticancer targeted agents
Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 94
Yamada, T., Iritani, M., Ohishi, H., Tanaka, K., Minoura, K., Doi, M., & Numata, A. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b713060k · Cited by 93
Combretastatin A4 Phosphate: A Novel Vascular Disrupting Agent
Nagaiah, G., & Remick, S. C. (2010) · Future Oncology · doi:10.2217/fon.10.90 · Cited by 92
A Crystal Structure of the Bifunctional Antibiotic Simocyclinone D8, Bound to DNA Gyrase
Edwards, M. J., Flatman, R. H., Mitchenall, L. A., Stevenson, C. E. M., Le, T. B. K., Clarke, T. A., McKay, A. R., Fiedler, H., Buttner, M. J., Lawson, D. M., et al. (2009) · Science · doi:10.1126/science.1179123 · Cited by 90
Kawiak, A., Piosik, J., Stasiłojć, G., Gwizdek‐Wiśniewska, A., Marczak, Ł., Stobiecki, M., Bigda, J., & Łojkowska, E. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.05.018 · Cited by 89
Dietary flavonoids induce MLL translocations in primary human CD34+ cells
van Doorn-Khosrovani, S. B. V. W., Janssen, J. W. H., Maas, L. M., Godschalk, R., Nijhuis, J. G., & van Schooten, F. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm102 · Cited by 89
Youns, M., Efferth, T., Reichling, J., Fellenberg, K., Bauer, A. S., & Hoheisel, J. D. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.014 · Cited by 88
Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage
Schonn, I., Hennesen, J., & Dartsch, D. C. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0440-9 · Cited by 85
Daigle, N. D., Carpentier, G. A., Frenette‐Cotton, R., Simard, M. G., Lefoll, M., Noël, M., Caron, L., Noël, J., & Isenring, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21814 · Cited by 85
Yang, F., Chen, Y., Duan, W., Zhang, C., Zhu, H., & Ding, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.21943 · Cited by 81
Li, Y., Luan, Y., Qi, X., Li, M., Gong, L., Xue, X., Wu, X., Wu, Y., Chen, M., Xing, G., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq282 · Cited by 81
Sperling, A. S., Jeong, K. S., Kitada, T., & Grunstein, M. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106834108 · Cited by 79
Lu, H., Zhu, H., Huang, M., Chen, Y., Cai, Y.-J., Miao, Z., Zhang, J., & Ding, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011544 · Cited by 79
11q23/MLL Acute Leukemia : Update of Clinical Aspects
Tamai, H., & Inokuchi, K. (2010) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.50.91 · Cited by 79
Crystal Structure of an Intact Type II DNA Topoisomerase: Insights into DNA Transfer Mechanisms
Graille, M., Cladière, L., Christiane, D. D., Lecointe, F., Gadelle, D., Quevillon‐Chéruel, S., Vachette, P., Forterre, P., & TILBEURGH, H. V. (2008) · Structure · doi:10.1016/j.str.2007.12.020 · Cited by 76
Kim, J. S., Rhee, H., Park, H. J., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.049 · Cited by 76
A Journey in the World of DNA Rings and Beyond
Wang, J. C. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.030107.090101 · Cited by 76
R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II
Zhu, H., Huang, M., Yang, F., Chen, Y., Miao, Z., Qian, X. H., Xu, Y. F., Qin, Y., Luo, H.-B., Shen, X., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0584 · Cited by 76
Park, I., Park, K.-K., Park, J. H. Y., & Chung, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.005 · Cited by 74
Mateos, M., Cibeira, M. T., Richardson, P. G. G., Prósper, F., Oriol, A., de la Rubia, J., Lahuerta, J. J., García‐Sánz, R., Extremera, S., Szyldergemajn, S. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0469 · Cited by 74
Cholody, W. M., Martelli, S., & Konopa, J. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00080a026 · Cited by 71
Woo, S., Jung, J. Y., Lee, C., Kwon, Y., & Na, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.030 · Cited by 71
Składanowski, A., Plisov, S. Y., Konopa, J., & Larsen, A. K. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09053-4 · Cited by 69
Inhibition of topoisomerase IIα: Novel function of wedelolactone
Beneš, P., Knopfová, L., Trčka, F., Nemajerová, A., Pinheiro, D., Souček, K., Fojta, M., & Šmarda, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.002 · Cited by 68
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
Kogan, N. M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., & Mechoulam, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0039 · Cited by 68
López‐Lázaro, M., Calderón‐Montaño, J. M., Burgos‐Morón, E., & Austin, C. A. (2011) · Mutagenesis · doi:10.1093/mutage/ger006 · Cited by 68
Kang, K., Oh, S. H., Yun, J. H., Jho, E. H., Kang, J., Batsurén, D., Tunsag, J., Park, K. H., Kim, M., & Nho, C. W. (2011) · Neoplasia · doi:10.1593/neo.11972 · Cited by 67
Chashoo, G., Singh, S. K., Sharma, P. R., Mondhe, D. M., Hamid, A., Saxena, A., Andotra, S. S., Shah, B. A., Ahmed, Q. N., Taneja, S. C., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.10.017 · Cited by 67
In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues
Wang, W., Rayburn, E. R., Velu, S. E., Nadkarni, D. H., Srinivasan, M., & Zhang, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2689 · Cited by 67
Byl, J. A. W., Fortune, J. M., Burden, D. A., et al. (1999) · Biochemistry · doi:10.1021/bi991791o · Cited by 66
Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells
López‐Lázaro, M., Willmore, E., Jobson, A. G., Gilroy, K. L., Curtis, H., Padget, K., & Austin, C. A. (2007) · Journal of Natural Products · doi:10.1021/np070332i · Cited by 65
Cells Lacking DNA Topoisomerase IIβ are Resistant to Genistein
López‐Lázaro, M., Willmore, E., & Austin, C. A. (2007) · Journal of Natural Products · doi:10.1021/np060609z · Cited by 65
Hazeldine, S. T., Polin, L., Kushner, J., White, K., Corbett, T. H., Biehl, J., & Horwitz, J. P. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.11.034 · Cited by 65
Corbett, T. H., LoRusso, P. M., Demchik, L. L., Simpson, C., Pugh, S., White, K., Kushner, J., Polin, L., Meyer, J., Czarnecki, J., et al. (1998) · Investigational New Drugs · doi:10.1023/a:1006174622061 · Cited by 64
Type II topoisomerases--inhibitors, repair mechanisms and mutations
Heisig, P. (2009) · Mutagenesis · doi:10.1093/mutage/gep035 · Cited by 63
Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives
Chen, S., Wang, Y.-H., Jin, Y., Tian, X., Zheng, Y., Luo, D., & Tu, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.070 · Cited by 63
Novel activity of acriflavine against colorectal cancer tumor cells
Hassan, S. B., Laryea, D., Mahteme, H., Felth, J., Fryknäs, M., Fayad, W., Linder, S. T., Rickardson, L., Gullbo, J., Graf, W., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02097.x · Cited by 60
Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases
Casu, L., Cottiglia, F., Leonti, M., Logu, A. D., Agus, E., Tse‐Dinh, Y., Lombardo, V., & Sissi, C. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.097 · Cited by 60
Kimura, S. H., Ito, C., Jyoko, N., Segawa, H., Kuroda, J., Okada, M., Adachi, S., Nakahata, T., Yuasa, T., Filho, V. C., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20505 · Cited by 59
Galal, S. A., Hegab, K. H., Hashem, A. M., & Youssef, N. S. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.023 · Cited by 59
Walsby, E. J., Coles, S., Knapper, S., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.032680 · Cited by 59
Dietary Isothiocyanate-induced Apoptosis via Thiol Modification of DNA Topoisomerase IIα
Lin, R.-K., Zhou, N., Lyu, Y. L., Tsai, Y.-C., Lu, C.-H., Kerrigan, J. E., Chen, Y.-T., Guan, Z., Hsieh, T., & Liu, L. F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.258137 · Cited by 58
Preclinical antitumor activity of XK469 (NSC 656889)
LoRusso, P. M., Parchment, R. E., Demchik, L. L., Knight, J., Polin, L., Dzubow, J., Behrens, C. H., Harrison, B., Trainor, G. L., & Corbett, T. H. (1998) · Investigational New Drugs · doi:10.1023/a:1006206814025 · Cited by 57
Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics
Portugal, J. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033482215 · Cited by 56
Resveratrol induces DNA double-strand breaks through human topoisomerase II interaction
Leone, S., Cornetta, T., Basso, E., & Cozzi, R. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.022 · Cited by 56
Cai, Y.-J., Lu, J., Zhu, H., Xie, H., Huang, M., Lin, L., Zhang, X., & Ding, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.017 · Cited by 54
Hisatomi, T., Sueoka‐Aragane, N., Sato, A., Tomimasu, R., Ide, M., Kurimasa, A., Okamoto, K., Kimura, S. H., & Sueoka, E. (2011) · Blood · doi:10.1182/blood-2010-02-270439 · Cited by 53
Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor
Prescott, T. A. K., Sadler, I. H., Kiapranis, R., & Maciver, S. K. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.07.036 · Cited by 53
Lemke, K. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki904 · Cited by 53
Identification of genomic regions contributing to etoposide-induced cytotoxicity
Bleibel, W. K., Duan, S., Huang, R. S., Kistner, E. O., Shukla, S. J., Wu, X., Badner, J. A., & Dolan, M. E. (2008) · Human Genetics · doi:10.1007/s00439-008-0607-4 · Cited by 53
Marshall, K. M., Matsumoto, S. S., Holden, J. A., Concepción, G. P., Taşdemir, D., Ireland, C. M., & Barrows, L. R. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00209-0 · Cited by 52
Stilbenoids of Kobresia nepalensis (Cyperaceae) exhibiting DNA topoisomerase II inhibition
Yamada, M., Hayashi, K., Hayashi, H., Ikeda, S., Hoshino, T., Tsutsui, K., Tsutsui, K., Iinuma, M., & Nozaki, H. (2005) · Phytochemistry · doi:10.1016/j.phytochem.2005.11.001 · Cited by 51
Identification of a Small-Molecule Inhibitor of DNA Topoisomerase II by Proteomic Profiling
Kawatani, M., Takayama, H., Muroi, M., Kimura, S. H., Maekawa, T., & Osada, H. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.03.012 · Cited by 51
Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma
Shen, W., Zou, X., Chen, M., Liu, P., Shen, Y., Huang, S., Guo, H., & Zhang, L. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.042 · Cited by 50
Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity
Dzięgielewski, J., Ślusarski, B., Könitz, A., Składanowski, A., & Konopa, J. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00916-4 · Cited by 49
Patra, N., De, U., Kang, J., Kim, J. M., Ahn, M. Y., Lee, J., Jung, J. H., Chung, H. Y., Moon, H. R., & Kim, H. S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.015 · Cited by 48
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors
Wu, W.-B., Ou, J., Huang, Z., Chen, S.-B., Ou, T., Tan, J., Li, D., Shen, L., Huang, S., Gu, L., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.04.059 · Cited by 47
Fayad, W., Fryknäs, M., Brnjic, S., Olofsson, M. H., Larsson, R. L., & Linder, S. T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007238 · Cited by 47
Isambert, N., Campone, M., Bourbouloux, E., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.005 · Cited by 46
Skwarska, A., Augustin, E., & Konopa, J. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0144-y · Cited by 46
Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones
Rhee, H., Park, H. J., Lee, S. K., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.12.012 · Cited by 45
Lancet, J. E., Ravandi, F., Ricklis, R. M., Cripe, L. D., Kantarjian, H. M., Giles, F. J., List, A. F., Chen, T., Allen, R. S., Fox, J. A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.157 · Cited by 44
Yan (2011) · Oncology Reports · doi:10.3892/or.2011.1189 · Cited by 44
Brel, V., Annereau, J., Vispé, S., Kruczynski, A., Bailly, C., & Guilbaud, N. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.028 · Cited by 43
Self-citationBurger, A., Double, J. A., Konopa, J., & Bibby, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.551 · Cited by 43
Chen, X., Gao, F., Zhou, Z., Yang, W., Guo, L.-T., & Ji, L. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.01.010 · Cited by 42
How to develop a successful cancer drug – molecules to medicines or targets to treatments?
Newell, D. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.12.024 · Cited by 42
Bram, E. E., Ifergan, I., Grimberg, M., Lemke, K., Składanowski, A., & Assaraf, Y. G. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.028 · Cited by 41
Beckford, F. A., Thessing, J., Shaloski, M., Mbarushimana, P. C., Brock, A., Didion, J., Woods, J., González‐Sarrías, A., & Seeram, N. P. (2011) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2011.02.029 · Cited by 41
Hsiao, C., Li, T., Chan, Y., Hsin, L., Liao, C.-H., Lee, C.-H., Lyu, P. C., & Guh, J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.012 · Cited by 41
Gao, H., Yamasaki, E. F., Chan, K. K., Shen, L. L., & Snapka, R. M. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1382 · Cited by 41
Kohrt, H. E. K., Patel, S. A., Ho, M., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21857 · Cited by 40
Noble, C. G., Barnard, F. M., & Maxwell, A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.854-862.2003 · Cited by 40
Tian, Z., Xie, S., Mei, Z.-H., Zhao, J., Gao, W., & Wang, C. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b912685f · Cited by 40
Hawtin, R. E., Stockett, D. E., Wong, O. K., Lundin, C., Helleday, T., & Fox, J. A. (2010) · Oncotarget · doi:10.18632/oncotarget.195 · Cited by 39
Burger, A., Jenkins, T. C., Double, J. A., & Bibby, M. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690702 · Cited by 39
Sperry, J., Lorenzo-Castrillejo, I., Brimble, M. A., & Machín, F. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.064 · Cited by 37
Villalona-Calero, M. A., Eder, J. P., Toppmeyer, D., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.857 · Cited by 37
Lin, H., Liu, X. Y., Subramanian, B., Nakeff, A., Valeriote, F. A., & Chen, B. D. (2001) · International Journal of Cancer · doi:10.1002/ijc.1570 · Cited by 36
Zaffaroni, N., Marco, C. D., Villa, R., Riboldi, S., Daidone, M. G., & Double, J. A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00227-1 · Cited by 36
Shah, B. A., Kaur, R., Gupta, P., Kumar, A., Sethi, V. K., Andotra, S. S., Singh, J., Saxena, A. K., & Taneja, S. C. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.089 · Cited by 36
Hyzy, M., Bozko, P. M., Konopa, J., & Składanowski, A. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.028 · Cited by 36
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
Joannides, M., Mays, A. N., Mistry, A. R., Hasan, S. K., Reiter, A., Wiemels, J. L., Felix, C. A., Lo‐Coco, F., Osheroff, N., Solomon, E., et al. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.045 · Cited by 35
Local sensing of global DNA topology: from crossover geometry to type II topoisomerase processivity
Timsit, Y. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr556 · Cited by 35
Jin, L., Tabe, Y., Kimura, S. H., Zhou, Y.-K., Kuroda, J., Asou, H., Inaba, T., Konopleva, M. Y., Andreeff, M., & Miida, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606007 · Cited by 35
Gilroy, K. L., & Austin, C. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014693 · Cited by 34
Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells
Gonzalez, R. E., Lim, C., Cole, K., Hanko, C., Schools, G. P., Davis, B. E., Wada, I., Roninson, I. B., & Broude, E. V. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17778 · Cited by 34
Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines
Shinkre, B. A., Raisch, K. P., Fan, L., & Velu, S. E. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.051 · Cited by 33
The Impact of the Human DNA Topoisomerase II C-Terminal Domain on Activity
Meczes, E. L., Gilroy, K. L., West, K. L., & Austin, C. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001754 · Cited by 33
Ding, Z., Parchment, R. E., LoRusso, P. M., Zhou, J. Y., Li, J., Lawrence, T. S., Sun, Y., & Wu, G. S. (2001) · PubMed · Cited by 33
Sadiq, A. A., Patel, M. R., Jacobson, B. A., Escobedo, M., Ellis, K. C., Oppegard, L. M., Hiasa, H., & Kratzke, R. A. (2009) · Investigational New Drugs · doi:10.1007/s10637-008-9209-1 · Cited by 33
Wu, H., & Jan, T. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.02.012 · Cited by 32
Neukam, K., Pastor, N., & Cortés, F. (2008) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.03.013 · Cited by 32
Cadmium is a catalytic inhibitor of DNA topoisomerase II
Wu, X., Yalowich, J. C., & Hasinoff, B. B. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.02.007 · Cited by 32
Lanoue, L., Green, K., Kwik-Uribe, C. L., & Keen, C. L. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009184 · Cited by 32
Naphthalimides Induce G2 Arrest Through the ATM-Activated Chk2-Executed Pathway in HCT116 Cells
Zhu, H., Miao, Z., Huang, M., Feng, J., Zhang, Z.-X., Lu, J., Cai, Y.-J., Tong, L., Xu, Y. F., Qian, X. H., et al. (2009) · Neoplasia · doi:10.1593/neo.09986 · Cited by 31
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer
Wang, F., Ezell, S. J., Zhang, Y., Wang, W., Rayburn, E. R., Nadkarni, D. H., Srinivasan, M., Velu, S. E., & Zhang, R. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9232-x · Cited by 31
Patupilone in cancer treatment
Bystrický, B., & Chau, I. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.542148 · Cited by 31
Synthesis of rotenoid derivatives with cytotoxic and topoisomerase II inhibitory activities
Sangthong, S., Krusong, K., Ngamrojanavanich, N., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.052 · Cited by 31
Tselepi, M., Papachristou, E., Emmanouilidi, A., Angelis, A., Aligiannis, N., Skaltsounis, A., Kouretas, D., & Liadaki, K. N. (2011) · Journal of Natural Products · doi:10.1021/np200292u · Cited by 31
Sargent, J. M., Elgie, A. W., Williamson, C. J., & Hill, B. T. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200307000-00013 · Cited by 31
Use of Yeast Chemigenomics and COXEN Informatics in Preclinical Evaluation of Anticancer Agents
Smith, S. C., Havaleshko, D. M., Moon, K. H., Baras, A. S., Lee, J., Bekiranov, S., Burke, D. J., & Theodorescu, D. (2011) · Neoplasia · doi:10.1593/neo.101214 · Cited by 30
Kalfalah, F. M., Mielke, C., Christensen, M. O., Baechler, S. A., Marko, D., & Boege, F. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201000509 · Cited by 30
Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells
Augustin, E., Wheatley, D. N., Lamb, J., & Konopa, J. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050445 · Cited by 30
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor
Gheeya, J., Johansson, P. A., Chen, Q., Dexheimer, T. S., Metaferia, B. B., Song, Y., Wei, J. S., He, J., Pommier, Y. G., & Khan, J. I. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.01.004 · Cited by 30
Guo, L., Liu, X., Nishikawa, K., & Plunkett, W. K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0780 · Cited by 30
C60-Fullerene Binds with the ATP Binding Domain of Human DNA Topoiosmerase II Alpha
Baweja, L., Gurbani, D., Shanker, R., Pandey, A., Subramanian, V., & Dhawan, A. (2011) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2011.1257 · Cited by 30
Rao, V. A., Zhang, J., Klein, S. R., Espandiari, P., Knapton, A. D., Dickey, J. S., Herman, E. H., & Shacter, E. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1587-y · Cited by 29
Shen, Y., Chang, Y., Lin, C., Liaw, C., Kuo, Y. H., Tu, L.-C., Yeh, S. F., & Chern, J. (2011) · Marine Drugs · doi:10.3390/md9020256 · Cited by 29
Mapping Simocyclinone D8 Interaction with DNA Gyrase: Evidence for a New Binding Site on GyrB
Sissi, C., Vazquez, E., Chemello, A. J., Mitchenall, L. A., Maxwell, A., & Palumbo, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00972-09 · Cited by 28
Kessel, D. H., Reiners, J. J., Hazeldine, S. T., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0386 · Cited by 28
Gomez-Monterrey, I. M., Campiglia, P., Aquino, C., Bertamino, A., Granata, I., Carotenuto, A., Brancaccio, D., Stiuso, P., Scognamiglio, I., Rusciano, M. R., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200094h · Cited by 28
Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer
Capizzi, R. L., Roman, L., Tjulandin, S. A., Смирнова, И. А., Manikhas, A., Paterson, J., Major, A., Lundberg, A. S., & Fumoleau, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1055 · Cited by 27
Na, Y., & Nam, J.-M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.037 · Cited by 27
Ishimaru, C., Yonezawa, Y., Kuriyama, I., Nishida, M., Yoshida, H., & Mizushina, Y. (2008) · Lipids · doi:10.1007/s11745-007-3149-y · Cited by 26
Liang, X., Xu, Y. F., Xu, K., Liu, J., & Qian, X. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0341 · Cited by 26
New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers
Cho, H.-J., Jung, M.-J., Woo, S., Kim, J.-S., Lee, E.-S., Kwon, Y., & Na, Y. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.069 · Cited by 25
Marverti, G., Ligabue, A., Montanari, M., Guerrieri, D., Cusumano, M., Pietro, M. L. D., Troiano, L., Vono, E. D., Iotti, S., Farruggia, G., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9336-3 · Cited by 25
Potęga, A., Dabrowska, E., Niemira, M., Kot‐Wasik, A., Ronseaux, S., Henderson, C. J., Wolf, C. R., & Mazerska, Z. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038984 · Cited by 24
Dittrich, C., Dieras, V. C., Kerbrat, P., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1025476813365 · Cited by 23
Chen, H., Bi, W., Cao, B., Yang, Z., Chen, S., Shang, H., Yu, P., & Yang, J. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.056 · Cited by 23
Anderson, L. W., Collins, J. M., Klecker, R. W., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0962-3 · Cited by 23
Bram, E. E., Adar, Y., Mesika, N., Sabisz, M., Składanowski, A., & Assaraf, Y. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054791 · Cited by 23
Wang, F., Tian, X., Huang, C., Li, Q., & Zhang, S. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.153 · Cited by 22
Paradziej-Łukowicz, J., Skwarska, A., Peszyńska-Sularz, G., Brillowska‐Dąbrowska, A., & Konopa, J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.7.15980 · Cited by 22
Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha
Bau, J. T., & Kurz, E. U. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.009 · Cited by 21
Liang, X., Wu, A., Xu, Y. F., Xu, K., Liu, J., & Qian, X. H. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9403-9 · Cited by 21
Kruczynski, A., Barret, J.-M. M., van Hille, B., Chansard, N., Astruc, J., Menon, Y., Duchier, C., Créancier, L., & Hill, B. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1305-2 · Cited by 21
Fedejko-Kap, B., Niemira, M., Radominska-p, A., & Mazerska, Z. (2011) · Xenobiotica · doi:10.3109/00498254.2011.604743 · Cited by 20
Krug, L. M., Crawford, J., Ettinger, D. S., Shapiro, G. I., Spigel, D. R., Reiman, T., Temel, J. S., Michelson, G. C., Young, D. Y., Hoch, U., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318200e509 · Cited by 20
Matuszak, N., Hamtiaux, L., Baldeyroux, B., Muccioli, G. G., Poupaert, J. H., Lansiaux, A., & Lambert, D. M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.11.011 · Cited by 20
Guo, L., Liu, X., Jiang, Y., Nishikawa, K., & Plunkett, W. K. (2011) · Molecular Pharmacology · doi:10.1124/mol.109.057125 · Cited by 20
Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells
Pourpak, A., Landowski, T. H., & Dorr, R. T. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117457 · Cited by 20
Synthesis and Antiproliferative Activity of Some Ellipticine‐Like 11H‐Pyrido[a]carbazole Derivatives
Ferlin, M. G., Gia, O. M., & Via, L. D. (2011) · ChemMedChem · doi:10.1002/cmdc.201100233 · Cited by 18
Chelouah, S., Monod, C., Bailly, C., Barret, J.-M. M., Guilbaud, N., Vispé, S., & Käs, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023597 · Cited by 17
Self-citationChen, M., Pan, S., Shi, Q., Xiao, Z., Lee, K., Li, T., & Teng, C. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02103.x · Cited by 17
Intracellular Succinylation of 8-Chloroadenosine and Its Effect on Fumarate Levels
Dennison, J. B., Ayres, M., Kaluarachchi, K. K., Plunkett, W. K., & Gandhi, V. V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085803 · Cited by 17
Congdon, L. M., Pourpak, A., Escalante, A. M., Dorr, R. T., & Landowski, T. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.026 · Cited by 17
Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues
Woo, S., Kang, D.-H., Nam, J. M., Lee, C. S., Ha, E.-M., Lee, E.-S., Kwon, Y., & Na, Y. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.06.017 · Cited by 17
Xie, C., Zhu, H., Lin, L., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0014 · Cited by 17
Xu, D., Cao, J., Qian, S., Li, L., Hu, C., Weng, Q., Lou, J.-S., Zhu, D., Zhu, H., Hu, Y., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9423-5 · Cited by 16
Dai, M., Miao, Z., Ren, X., Tong, L., Yang, N., Li, T., Lin, L., Shen, Y., & Ding, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00822.x · Cited by 16
Seleno‐podophyllotoxin derivatives induce hepatoma SMMC‐7721 cell apoptosis through Bax pathway
Miao, R., Han, Y., An, L., Yang, J., & Wang, Q. (2007) · Cell Biology International · doi:10.1016/j.cellbi.2007.08.034 · Cited by 14
Selenite induces topoisomerase I and II‐DNA complexes in K562 leukemia cells
López‐Lázaro, M., Willmore, E., Elliott, S. L., & Austin, C. A. (2008) · International Journal of Cancer · doi:10.1002/ijc.23783 · Cited by 14
White, Y., Hamada, T., Yoshimitsu, M., Nakashima, M., Hachiman, M., Kozako, T., Matsushita, K., Uozumi, K., Suzuki, S., Kofune, H., et al. (2011) · PubMed · Cited by 14
Cited by
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
Marinello, J., Delcuratolo, M., & Capranico, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113480 · Cited by 258
Metadata
- Authors
- Bailly, C.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-03-08
- Volume
- 112
- Issue
- 7
- Pages
- 3611-3640
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2326231942
- Cited by
- 288
- References
- 209
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.